These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18344684)

  • 1. A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence.
    Shi Y; August DA
    Cancer Biol Ther; 2008 Mar; 7(3):397-8. PubMed ID: 18344684
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.
    Bu X; Le C; Jia F; Guo X; Zhang L; Zhang B; Wu M; Wei L
    Cancer Biol Ther; 2008 Mar; 7(3):392-6. PubMed ID: 18075305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The interaction between 5-fluorouracil and marini on QGY cell line in vitro].
    He S; Cheb S; Tang W; Zuo G; Shen W
    Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):160. PubMed ID: 12108392
    [No Abstract]   [Full Text] [Related]  

  • 6. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
    Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells.
    Bu X; Jia F; Wang W; Guo X; Wu M; Wei L
    BMC Cancer; 2007 Nov; 7():208. PubMed ID: 17996122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].
    Li SZ; Xu F; Sun CQ; Xu P
    Zhonghua Gan Zang Bing Za Zhi; 2018 Jan; 26(1):77-80. PubMed ID: 29804369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gerosuppression by pan-mTOR inhibitors.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2016 Dec; 8(12):3535-3551. PubMed ID: 28077803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
    J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
    Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
    Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.
    Leontieva OV; Blagosklonny MV
    Cell Cycle; 2014; 13(4):509-15. PubMed ID: 24496328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
    Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
    Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
    Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
    Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
    Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
    Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mTOR and P70 S6 kinase expression in primary liver neoplasms.
    Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
    Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-hepatocellular carcinoma cell activity by a novel mTOR kinase inhibitor CZ415.
    Zhang W; Chen B; Zhang Y; Li K; Hao K; Jiang L; Wang Y; Mou X; Xu X; Wang Z
    Biochem Biophys Res Commun; 2017 Jun; 487(3):494-499. PubMed ID: 28366631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.